Cover About Us Financial Highlights To Our Shareholders Operational Effectiveness Innovating for Impact     Healthcare Worker Safety     Patient Safety     Diabetes     Infectious Diseases     HIV/AIDS     Immunization     Drug Discovery Social Responsibility and BD     Vaccine Grants/Johns Hopkins University     Project Perfect World     U.S. Fund for UNICEF / MNT Enterprise Profile Financials     Notes to Consolidated Financial Statements     Financial Review     Financial Statements Corporate Information Board of Directors Corporate Officers Back Cover

The BD FACSCanto system adapts high performance BD FACSAria cell sorter technology to a "workhorse" analyzer for the clinical and clinical research markets. 's highly sophisticated instruments–such as the BD FACSCanto system introduced in 2004–enable researchers to better understand HIV/AIDS, which will hopefully lead someday to the development of an effective vaccine. BD also produces basic, but highly precise, products–for example, the auto-disable BD SoloShot VX and BD SoloMed syringes–that are critical in light of World Health Organization (WHO) estimates that 40 percent of all injections in the developing world are given with previously used devices. Additionally, it is estimated that reused devices cause 260,000 HIV/AIDS infections annually.     Sophisticated research as well as basic clinical technologies represent the broad spectrum of BD innovations focused on combating HIV/AIDS. As Krista Thompson, named to lead the HIV/AIDS strategy across BD, says, "It takes innovation to make things simple and affordable. We tend to think of innovation as highly technical and complex, but in order to battle this disease we need to get appropriate products to the people who need them."     In working toward a coordinated HIV/AIDS strategy, BD is seeking to leverage the research, prevention and diagnostic tools that it provides in each of its three business segments. Examples include BD FastImmune reagents along with flow cytometers from BD Biosciences, used by HIV vaccine researchers to assess immune response. BD Medical provides advanced protection devices that prevent reuse and help safeguard healthcare workers from the transmission of HIV and other diseases through accidental injuries caused by contaminated needles. BD Diagnostics technologies are used to diagnose and monitor many infectious diseases associated with HIV/AIDS. Notable among these is the BD BACTEC MGIT 960, which shortens the time required for detection and susceptibility testing of tuberculosis, a leading killer of AIDS patients globally. The Company is also broadening its global infrastructure with additional on-the-ground resources in Europe and Africa.     BD will seek to expand its role as a supplier and resource for government health ministries and public health agencies around the world, while also maintaining its philanthropic activities in the HIV/AIDS arena, through, for example, donations to the International AIDS Vaccine Initiative (IAVI). In a new collaboration, BD is working with the William J. Clinton Presidential Foundation to provide the developing world with affordable monitoring technologies for CD4 testing.     Thompson makes two additional observations about BD and its role in the battle against HIV/AIDS. First, BD is looking at HIV/AIDS as a disease state–that is, thinking about it holistically and bringing all of its resources to bear in much the same way it approaches diabetes. Second, she says, this will be a long battle for the world. "With a combination of philanthropic and sustainable business efforts, BD can marshal both current technologies and future innovations in a concerted effort to help defeat HIV/AIDS." BD MultiTEST immuno-fluorescence reagents, together with BD TruCOUNT tubes, provide a reliable and reproducible method for CD4 counting used to manage clinical care for persons infected with HIV. The newly developed BD SoloMed syringe is intended for the acute care environment in developing countries. An extra push after use breaks the plunger, preventing reuse. BD will also offer a safetyshielded version. Expected to reach the market in early 2005, the BD SoloShot VX-2 syringe permits variable dosing, enables medication to be reconstituted, and automatically locks after injection. In 2003, AIDS claimed almost 3 million lives around the world and nearly 5 million more people became newly infected with HIV. Young people–ages 15 to 24–account for nearly half of all new HIV infections worldwide. Despite signs of progress in funding, political commitment and access to treatment, the AIDS pandemic requires an extraordinary acceleration in global response. BD is answering this call by providing frontline products that are making contributions ranging from prevention to therapeutic monitoring. But if there is to be greater headway in this battle against HIV/AIDS, it will come through research and advanced diagnostics. The BD FACSCanto system serves as a powerful tool for researchers and clinicians seeking to understand this disease and the immune system.